Emerging drugs for acromegaly

Introduction: Acromegaly is a rare disease that severely impacts patients' health all the while, being a slowly progressing illness. In the past decades, advancements in treatment modalities, especially development of new drugs, as well as focused guidelines has improved management of acromegaly. Still, many patients are considered not sufficiently treated and there remains an ongoing need for further development. Areas covered: This article reviews new medical treatments currently under clinical investigation (such as pasireotide, oral octreotide and somatoprinn) and under experimental development (such as octreotide implants, CAM2029 and ATL-1103). Expert opinion: As it seems unlikely that one single agent may achieve cure in 100% of cases, there is an urgent need for new agents that help patients where current medication fails. Imperatively, this means we have to improve our understanding of the underlying pathogenetic and molecular mechanisms.